{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:48:38Z","timestamp":1792817318941,"version":"4.5.0"},"reference-count":33,"publisher":"Massachusetts Medical Society","issue":"18","license":[{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.nejmgroup.org\/legal\/terms-of-use.htm"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research & Development, LLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["N Engl J Med"],"published-print":{"date-parts":[[2025,5,8]]},"DOI":"10.1056\/nejmoa2409029","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T14:00:16Z","timestamp":1733752816000},"page":"1777-1788","source":"Crossref","is-referenced-by-count":121,"title":["Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma"],"prefix":"10.1056","volume":"392","author":[{"given":"Meletios A.","family":"Dimopoulos","sequence":"first","affiliation":[{"name":"Alexandra General Hospital, National and Kapodistrian University of Athens, Athens"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"Voorhees","sequence":"additional","affiliation":[{"name":"Levine Cancer Institute, Atrium Health Wake Forest University School of Medicine, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Schjesvold","sequence":"additional","affiliation":[{"name":"Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael C.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Tel-Aviv Sourasky (Ichilov) Medical Center and Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vania","family":"Hungria","sequence":"additional","affiliation":[{"name":"Cl\u00ednica Medica S\u00e3o Germano, S\u00e3o Paulo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irwindeep","family":"Sandhu","sequence":"additional","affiliation":[{"name":"Cross Cancer Institute, University of Alberta, Edmonton, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jindriska","family":"Lindsay","sequence":"additional","affiliation":[{"name":"Kent and Canterbury Hospital, Canterbury, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross I.","family":"Baker","sequence":"additional","affiliation":[{"name":"Perth Blood Institute, Murdoch University, Perth, WA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenshi","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Japanese Red Cross Medical Center, Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kosugi","sequence":"additional","affiliation":[{"name":"Ogaki Municipal Hospital, Ogaki City, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark-David","family":"Levin","sequence":"additional","affiliation":[{"name":"Albert Schweitzer Hospital, Dordrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meral","family":"Beksac","sequence":"additional","affiliation":[{"name":"Ankara University, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Stockerl-Goldstein","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine, St. Louis"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Oriol","sequence":"additional","affiliation":[{"name":"Institut Catal\u00e0 d\u2019Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabor","family":"Mikala","sequence":"additional","affiliation":[{"name":"South Pest Central Hospital, National Institute for Hematology and Infectious Diseases, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo","family":"Garate","sequence":"additional","affiliation":[{"name":"Hospital Alem\u00e1n, Buenos Aires"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"Theunissen","sequence":"additional","affiliation":[{"name":"Jessa Hospital, Hasselt, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Spicka","sequence":"additional","affiliation":[{"name":"Charles University and General Hospital, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne K.","family":"Mylin","sequence":"additional","affiliation":[{"name":"Rigshospitalet, University of Copenhagen, Copenhagen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Bringhen","sequence":"additional","affiliation":[{"name":"SSD Clinical Trials in Oncol-ematologia e Mieloma Multiplo, AOU Citt\u00e0 della Salute e della Scienza di Torino, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Uttervall","sequence":"additional","affiliation":[{"name":"Medical Unit Hematology, Karolinska University Hospital, Stockholm"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartosz","family":"Pula","sequence":"additional","affiliation":[{"name":"Institute of Hematology and Transfusion Medicine, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Medvedova","sequence":"additional","affiliation":[{"name":"Knight Cancer Institute, Oregon Health and Science University, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Cowan","sequence":"additional","affiliation":[{"name":"University of Washington and Fred Hutchinson Cancer Center, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[{"name":"University Hospital H\u00f4tel-Dieu, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Victoria","family":"Mateos","sequence":"additional","affiliation":[{"name":"University Hospital of Salamanca, IBSAL, and Cancer Research Center, IBMCC, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[{"name":"GMMG Study Group at University Hospital Heidelberg, Internal Medicine V, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahamtan","family":"Ahmadi","sequence":"additional","affiliation":[{"name":"Genmab US, Plainsboro, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Sha","sequence":"additional","affiliation":[{"name":"Janssen Research and Development, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelore","family":"Cortoos","sequence":"additional","affiliation":[{"name":"Janssen Scientific Affairs, Horsham, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva G.","family":"Katz","sequence":"additional","affiliation":[{"name":"Janssen Research and Development, Raritan, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Els","family":"Rousseau","sequence":"additional","affiliation":[{"name":"Janssen Research and Development, Beerse, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Li","sequence":"additional","affiliation":[{"name":"Janssen Research and Development, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn M.","family":"Dennis","sequence":"additional","affiliation":[{"name":"Janssen Research and Development, Raritan, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Carson","sequence":"additional","affiliation":[{"name":"Janssen Research and Development, Spring House, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"150","reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-568899"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00366-3"},{"key":"e_1_3_5_4_2","unstructured":"Darzalex (daratumumab) injection for intravenous use. Horsham PA: Janssen Biotech 2022 (package insert) (https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/DARZALEX-pi.pdf)."},{"key":"e_1_3_5_5_2","unstructured":"European Medicines Agency. Darzalex 20 mg\/mL concentrate for solution for infusion. Summary of product characteristics (https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/darzalex-epar-product-information_en.pdf)."},{"key":"e_1_3_5_6_2","doi-asserted-by":"crossref","unstructured":"Landgren O Chari A Cohen YC et al. Efficacy and safety of daratumumab (DARA) monotherapy in patients with intermediate-risk or high-risk smoldering multiple myeloma (SMM): final analysis of the phase 2 CENTAURUS study. Presented at: American Society of Hematology (ASH) Annual Meeting and Exposition San Diego CA December 9\u201312 2023.","DOI":"10.1182\/blood-2023-181765"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070389"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-05-088443"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-108357"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1300439"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404284"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-299487"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0006-341X.1999.01188.x"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0077-4"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-00980-5"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.11.024"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506348"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01120-4"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312054"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30070-3"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817249"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714678"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12051223"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.07.030"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01740"},{"key":"e_1_3_5_28_2","doi-asserted-by":"crossref","unstructured":"Usmani S Facon T Hungria V et al. Daratumumab SC + bortezomib\/lenalidomide\/dexamethasone in patients with transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: results of the phase 3 CEPHEUS study. Presented at: 21st International Myeloma Society (IMS) Annual Meeting Rio de Janeiro September 25\u201328 2024.","DOI":"10.1016\/S2152-2650(24)02344-9"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2400712"},{"key":"e_1_3_5_30_2","doi-asserted-by":"crossref","unstructured":"Hill E Roswarski JL Bhaskarla A et al. Fixed duration combination therapy with carfilzomib lenalidomide and dexamethasone followed by lenalidomide maintenance leads to high rates of sustained MRD negativity in patients with high-risk smoldering multiple myeloma: long term follow up of an investigator initiated phase 2 trial. Presented at: American Society of Hematology (ASH) Annual Meeting and Exposition San Diego CA December 9\u201312 2023.","DOI":"10.1182\/blood-2023-181811"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02771"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-168930"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00217-X"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-020-03227-y"}],"container-title":["New England Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa2409029","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T19:50:08Z","timestamp":1749239408000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa2409029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":33,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2025,5,8]]}},"alternative-id":["10.1056\/NEJMoa2409029"],"URL":"https:\/\/doi.org\/10.1056\/nejmoa2409029","relation":{},"ISSN":["0028-4793","1533-4406"],"issn-type":[{"value":"0028-4793","type":"print"},{"value":"1533-4406","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,8]]}}}